Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04085393
Recruitment Status : Withdrawn (sponsor withdrew study)
First Posted : September 11, 2019
Last Update Posted : September 30, 2020
Sponsor:
Collaborator:
Heron Therapeutics
Information provided by (Responsible Party):
Rudolph Navari, University of Alabama at Birmingham

Brief Summary:

Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions. The emetogenicity of the chemotherapy administered and specific patient characteristics such as female gender, age, and history of low alcohol intake can increase a patients' risk for CINV.

GERSC is a new, subcutaneously (SC) administered polymeric formulation of Granisetron that was developed to provide slow, controlled, and sustained release of Granisetron to prevent both acute and delayed CINV associated with moderately emetic chemotherapy (MEC) and highly emetic chemotherapy (HEC)


Condition or disease Intervention/treatment Phase
Chemotherapy-induced Nausea and Vomiting Drug: GRANISETRON EXTENDED RELEASE INJECTION (GERSC) Phase 2

Detailed Description:

All patients eligible for the study receiving moderately emetogenic (MEC) chemotherapy will receive GERSC receptor antagonist on day one. All patients eligible for the study receiving highly emetogenic Chemotherapy (HEC) chemotherapy will receive GERSC receptor antagonist on day one including dexamethasone and NK-1 Receptor antagonist during cycle 1.

The primary objective is to measure the Complete Response (no emetic episodes, no use of rescue medications) in patients receiving GERSC as a replacement for the second generation 5 HT3 receptor antagonist palonosetron used in the first chemotherapy cycle for those patients receiving MEC or HEC and developed Breakthrough CINV. Complete response would be recorded specifically for the acute (0-24 hours post-chemotherapy), delayed (24-120 hours post-chemotherapy), and overall periods (0-120 hours post-chemotherapy).

This study has two study groups.

  • Group 1 (HEC) will receive GERSC, dexamethasone and NK-1 antagonist prior to chemotherapy
  • Group 2 (MEC) will receive GERSC and dexamethasone prior to chemotherapy

During the study:

Participants will be completing questionnaires on day 1 prior to treatment and at approximately the same time treatment was given each day for the next seven days. Participant will be assessed each day on the amount of nausea, vomiting, and/or sedation experienced in the previous 24-hour period. The assessment should take less than 5 minutes to complete each day.

Participants will be registered for Quality of Life measurement. Validated QOL measurements of fatigue and overall perception of QOL will be assessed upon registration in this study. Fatigue and overall well-being clearly can impact how well patients will do in terms of being able to tolerate and experience nausea and vomiting

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Breakthrough Nausea and Vomiting (CINV) in Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Phase II Clinical Trial
Actual Study Start Date : August 15, 2020
Actual Primary Completion Date : August 15, 2020
Estimated Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Granisetron

Arm Intervention/treatment
Active Comparator: GERSC for patients receiving highly emetogenic chemotherapy
Participants will receive GERSC, and two other standard antiemetics prior to chemotherapy
Drug: GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy

Active Comparator: GERSC on patients receiving moderately emetogenic chemotherapy
Participants will receive GERSC and one other standard antiemetic prior to chemotherapy
Drug: GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy




Primary Outcome Measures :
  1. Percentage of participants with a previous history of emetic episodes [ Time Frame: Baseline assessment ]
    After participants have completed their informed consent, they will complete a baseline assessment to record emetic episodes prior to chemotherapy.

  2. Percentage of participants with a complete response of no emetic episode [ Time Frame: Baseline through 24 hours ]
    Patient will be monitored for vomiting on Day 1 after receiving chemotherapy. The participants will complete a vomiting assessment and record the number of episodes (none, once, more than once and number)

  3. Percentage of participants with a complete response of no emetic episode [ Time Frame: Day 2 through Day 6 ]
    Patient will be monitored for vomiting on Day 2 through Day 6 after receiving chemotherapy. The participants will complete a vomiting assessment and record the number of episodes (none, once, more than once and number)

  4. Percentage of participants with a complete response of no emetic episode [ Time Frame: Day 1 through Day 6 ]
    Patient will be monitored for total vomiting episodes starting from Day 1 through Day 6 after receiving chemotherapy. The participants will complete a vomiting assessment and record the number of episodes (none, once, more than once and number)


Secondary Outcome Measures :
  1. Percentage of participants frequency rate of No Nausea [ Time Frame: Baseline ]
    Participants will complete a Visual Analogue Scale at baseline to record their history of the presence or absence of nausea and frequency prior to chemotherapy. The scale range is between 0 - 10 (0 = No Nausea; 10 = Excessive Nausea).

  2. Percentage of participants frequency rate of No Nausea [ Time Frame: Baseline through 24 hours ]
    Participants will complete a Visual Analogue Scale on Day 1 to record the presence or absence of nausea and frequency after receiving chemotherapy. The scale range is between 0 - 10 (0 = No Nausea; 10 = Excessive Nausea).

  3. Percentage of participants frequency rate of No Nausea [ Time Frame: Day 2 through Day 6 ]
    Participants will complete a Visual Analogue Scale on Day 2 through Day 6 to record the presence or absence of nausea and frequency after receiving chemotherapy. The scale range is between 0 - 10 (0 = No Nausea; 10 = Excessive Nausea).

  4. Percentage of participants frequency rate of No Nausea [ Time Frame: Day 1 through Day 6 ]
    Participants will complete a Visual Analogue Scale on Day 1 through Day 6 to record the presence or absence of nausea and frequency after receiving chemotherapy. The scale range is between 0 - 10 (0 = No Nausea; 10 = Excessive Nausea).

  5. Percentage of participants experiencing GERSC toxicity [ Time Frame: Baseline through 30 days ]

    The toxicity will be assessed by the severity of the side effects listed below. The descriptions and grading scales found in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4 will be utilized for reporting.

    • Constipation
    • Fatigue
    • Headache
    • Diarrhea
    • Abdominal Pain
    • Sleeplessness (Insomnia)
    • Indigestion (Dyspepsia)
    • Dizziness
    • Asthenia
    • Gastroesophageal Reflux



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of malignant disease and scheduled for MEC or HEC
  • Chemotherapy naive
  • Age ≥18 years.
  • ECOG Performance Status 0 or 1
  • Required Initial Laboratory Values ≤28 days prior to registration. Patient must have adequate bone marrow, kidney, and liver function as evidenced by:
  • Platelet count ≥ 100,000/ mm3
  • Bilirubin ≤ 1.5 x ULN, except for subjects with Gilbert's syndrome
  • Serum Creatinine ≤2.0 mg/dL
  • SGOT or SGPT ≤3 x upper limit of normal (ULN)
  • Absolute neutrophil count (ANC) ≥1500/mm3
  • Patients receiving HEC will have received the 5HT3 receptor antagonist palonosetron, a NK-1, and dexamethasone as antiemetic prophylaxis during cycle 1 of chemotherapy
  • Patients receiving MEC will have received the 5HT3 receptor antagonist palonosetron, and dexamethasone as antiemetic prophylaxis during cycle 1 of chemotherapy

Exclusion Criteria:

  • No nausea or vomiting ≤ 24 hours prior to registration.
  • Negative pregnancy test (serum β hCG) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion).
  • No severe cognitive compromise.
  • No known history of active, untreated CNS disease (e.g. brain metastases, seizure disorder).
  • No concurrent use of amifostine, thioridazine, pimozide or St. John's wort.
  • No concurrent abdominal radiotherapy.
  • No concurrent use of olanzapine therapy.
  • No chronic alcoholism (as determined by the investigator).
  • No known hypersensitivity to granisetron.
  • No known uncontrolled cardiac arrhythmia or uncontrolled congestive heart failure.
  • No acute myocardial infarction within the previous six months.
  • No history of uncontrolled diabetes mellitus (may be on a stable dose of insulin or on a stable dose of an oral hypoglycemic agent).
  • Patients with psychiatric illness that would prevent the patient from giving informed consent are not eligible for the trial
  • Medical condition such as uncontrolled infection (including HIV),uncontrolled Diabetes Mellitus, unstable cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient are not eligible for the trial
  • Patients with a "currently active" second malignancy other than non-melanoma skin cancers are not eligible for the trial; Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
  • Patients who cannot swallow oral formulations of the agent(s) are not eligible for the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04085393


Locations
Layout table for location information
United States, Alabama
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Heron Therapeutics
Investigators
Layout table for investigator information
Principal Investigator: Rudolph M Navari, MD University of Alabama at Birmingham
Layout table for additonal information
Responsible Party: Rudolph Navari, Professro, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT04085393    
Other Study ID Numbers: UAB1950
First Posted: September 11, 2019    Key Record Dates
Last Update Posted: September 30, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nausea
Vomiting
Signs and Symptoms, Digestive
Granisetron
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action